Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Čemažar Maja) .

31 - 40 / 101
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
31.
Vinblastine increases antitumor effectiveness of bleomycin
Maja Čemažar, Marija Auersperg, Gregor Serša, 1997, izvirni znanstveni članek

Povzetek: In our previous vinblastine (VELBE) was shown to increase the plasma membrane fluidity. This effect of VELBE might be expolited for better transport of drugs through the plasma membrane. Bleomycin (BLM) is a highly cytotoxic drug when present inside the cells but has a hampered transport through the plasma membrane. The aim of the present study was to determine whether pretreatment with VELBE can increase the effect of BLM on intraperitoneal SA-1 tumors in mice. BLM and VELBE were used as single agents or in various combinations, i.e. VELBE and BLM injected simultanously, BLM injected 24 h before VELBE or VELBE injected 24 h before BLM. Mice survival was the end-point used for determining the effect of this combined treatments. VELBE and BLM as a single treatment significantly prolonged median survival time of study animals compared to controls. Furthermore, when VELBE and BLM were combined, all threetested combinations were more effective than VELBE or BLM as single treatments. The effect on animal survival was equal when VELBE was given 24 h after or simultanously with BLM. The longest survival, however was obtained when VELBE was injected 24 h before BLM. From these results we can conclude that the underlying mechanisms for more than additive effect of VELBE and BLM when VELBE was given 24 h before BLM could be attributed to an increased membrane fluidity, possibly in combination with a cell kinetic effect.
Objavljeno v DiRROS: 18.01.2024; Ogledov: 149; Prenosov: 35
.pdf Celotno besedilo (1,28 MB)

32.
33.
34.
35.
36.
37.
38.
Radiosenzibilizacija tumorjev z elektroprenosom plazmida za dve antiangiogeni tarči
Monika Savarin, Katarina Žnidar, Gregor Serša, Tilen Komel, Maja Čemažar, Urška Kamenšek, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: miši, elektroprenos genov, gensko zdravljenje
Objavljeno v DiRROS: 19.06.2023; Ogledov: 333; Prenosov: 131
.pdf Celotno besedilo (310,08 KB)
Gradivo ima več datotek! Več...

39.
Razvoj in karakterizacija mišjega modela za študije HPV-pozitivnega raka glave in vratu
Živa Modic, Maja Čemažar, Boštjan Markelc, Andrej Cör, Gregor Serša, Simona Kranjc Brezar, Tanja Jesenko, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: miši, rak glave in vratu, gensko zdravljenje
Objavljeno v DiRROS: 19.06.2023; Ogledov: 366; Prenosov: 159
.pdf Celotno besedilo (361,47 KB)
Gradivo ima več datotek! Več...

40.
Aktivacija vzorčno prepoznavnih senzorjev po genskem elektroprenosu plazmida z zapisom za interlevkin-12
Ajda Medved, Tanja Jesenko, Gregor Serša, Maša Omerzel, Maja Čemažar, 2023, objavljeni povzetek znanstvenega prispevka na konferenci

Ključne besede: miši, obsevanje, gensko zdravljenje
Objavljeno v DiRROS: 19.06.2023; Ogledov: 326; Prenosov: 154
.pdf Celotno besedilo (457,33 KB)
Gradivo ima več datotek! Več...

Iskanje izvedeno v 0.17 sek.
Na vrh